Representative recent publications of SWG members:
Deep Morphology Learning Enhances Ex Vivo Drug Profiling-Based Precision Medicine. Heinemann T, Kornauth C, Severin Y, Vladimer GI, Pemovska T, Hadzijusufovic E, Agis H, Krauth MT, Sperr WR, Valent P, Jäger U, Simonitsch-Klupp I, Superti-Furga G, Staber PB, Snijder B. Blood Cancer Discov. 2022 Nov 2;3(6):502-515. doi: 10.1158/2643-3230.BCD-21-0219. PMID: 36125297
Metabolic drug survey highlights cancer cell dependencies and vulnerabilities. Pemovska T, Bigenzahn JW, Srndic I, Lercher A, Bergthaler A, César-Razquin A, Kartnig F, Kornauth C, Valent P, Staber PB, Superti-Furga G. Nat Commun. 2021 Dec 14;12(1):7190. doi: 10.1038/s41467-021-27329-x. PMID: 34907165
Implementing a Functional Precision Medicine Tumor Board for Acute Myeloid Leukemia. Malani D, Kumar A, Brück O, Kontro M, Yadav B, Hellesøy M, Kuusanmäki H, Dufva O, Kankainen M, Eldfors S, Potdar S, Saarela J, Turunen L, Parsons A, Västrik I, Kivinen K, Saarela J, Räty R, Lehto M, Wolf M, Gjertsen BT, Mustjoki S, Aittokallio T, Wennerberg K, Heckman CA, Kallioniemi O, Porkka K. Cancer Discov. 2022 Feb;12(2):388-401. doi: 10.1158/2159-8290.CD-21-0410. Epub 2021 Nov 17. PMID: 34789538
Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematologic Cancers and Identifies Exceptional Responders. Kornauth C, Pemovska T, Vladimer GI, Bayer G, Bergmann M, Eder S, Eichner R, Erl M, Esterbauer H, Exner R, Felsleitner-Hauer V, Forte M, Gaiger A, Geissler K, Greinix HT, Gstöttner W, Hacker M, Hartmann BL, Hauswirth AW, Heinemann T, Heintel D, Hoda MA, Hopfinger G, Jaeger U, Kazianka L, Kenner L, Kiesewetter B, Krall N, Krajnik G, Kubicek S, Le T, Lubowitzki S, Mayerhoefer ME, Menschel E, Merkel O, Miura K, Müllauer L, Neumeister P, Noesslinger T, Ocko K, Öhler L, Panny M, Pichler A, Porpaczy E, Prager GW, Raderer M, Ristl R, Ruckser R, Salamon J, Schiefer AI, Schmolke AS, Schwarzinger I, Selzer E, Sillaber C, Skrabs C, Sperr WR, Srndic I, Thalhammer R, Valent P, van der Kouwe E, Vanura K, Vogt S, Waldstein C, Wolf D, Zielinski CC, Zojer N, Simonitsch-Klupp I, Superti-Furga G, Snijder B, Staber PB. Cancer Discov. 2022 Feb;12(2):372-387. doi: 10.1158/2159-8290.CD-21-0538. Epub 2021 Oct 11. PMID: 34635570
Rationale for the combination of venetoclax and ibrutinib in T-prolymphocytic leukemia. Kornauth C, Herbaux C, Boidol B, Guillemette C, Caron P, Mayerhöfer ME, Poulain S, Tournilhac O, Pemovska T, Chong SJF, Van der Kouwe E, Kazianka L, Hopfinger G, Heintel D, Jäger R, Raderer M, Jäger U, Simonitsch-Klupp I, Sperr WR, Kubicek S, Davids MS, Staber PB. Haematologica. 2021 Aug 1;106(8):2251-2256. doi: 10.3324/haematol.2020.271304. PMID: 33626863
Precision Medicine in Hematology 2021: Definitions, Tools, Perspectives, and Open Questions. Valent P, Orfao A, Kubicek S, Staber P, Haferlach T, Deininger M, Kollmann K, Lion T, Virgolini I, Winter G, Hantschel O, Kenner L, Zuber J, Grebien F, Moriggl R, Hoermann G, Hermine O, Andreeff M, Bock C, Mughal T, Constantinescu SN, Kralovics R, Sexl V, Skoda R, Superti-Furga G, Jäger U. Hemasphere. 2021 Feb 17;5(3):e536. doi: 10.1097/HS9.0000000000000536. eCollection 2021 Mar. PMID: 33623882
BH3 profiling identifies ruxolitinib as a promising partner for venetoclax to treat T-cell prolymphocytic leukemia. Herbaux C, Kornauth C, Poulain S, Chong SJF, Collins MC, Valentin R, Hackett L, Tournilhac O, Lemonnier F, Dupuis J, Daniel A, Tomowiak C, Laribi K, Renaud L, Roos-Weil D, Rossi C, Van Den Neste E, Leyronnas C, Merabet F, Malfuson JV, Tiab M, Ysebaert L, Ng S, Morschhauser F, Staber PB, Davids MS. Blood. 2021 Jun 24;137(25):3495-3506. doi: 10.1182/blood.2020007303. PMID: 33598678
Next generation proteomics with drug sensitivity screening identifies sub-clones informing therapeutic and drug development strategies for multiple myeloma patients. Tierney C, Bazou D, Majumder MM, Anttila P, Silvennoinen R, Heckman CA, Dowling P, O'Gorman P. Sci Rep. 2021 Jun 18;11(1):12866. doi: 10.1038/s41598-021-90149-y. PMID: 34145309
Back